Vimarsana
Biggest News Aggregation in the World

Gil Wolfe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gil Wolfe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gil Wolfe Today - Breaking & Trending Today

First CRISPR drug could be approved soon – DW – 11/02/2023 - Vimarsana News

First CRISPR drug could be approved soon – DW – 11/02/2023

A CRISPR drug to treat sickle cell disease may be approved by the US drug regulator next month.

Source: dw.com
Potential cure for sickle cell disease raises few concerns for FDA panel - Vimarsana News

Potential cure for sickle cell disease raises few concerns for FDA panel

Vertex Pharmaceuticals has hailed its treatment as "transformative" for patients with sickle cell disease. The FDA will decide on approval soon.

FDA considers first CRISPR gene editing treatment that may cure sickle cell - Boston News, Weather, Sports - Vimarsana News

FDA considers first CRISPR gene editing treatment that may cure sickle cell - Boston News, Weather, Sports

(CNN) — At age 45, Dr. Lakiea Bailey said, for the longest time, that she was the oldest person with sickle cell anemia that she knew. The executive<a class="excerpt-read-more" href="https://whdh.com/news/fda-considers-first-crispr-gene-editing-treatment-that-may-cure-sickle-cell/">Read More</a>

Source: whdh.com
Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions - Vimarsana News

Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression in generalized myasthenia...

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions - Vimarsana News

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including mini...